A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

NCT05183958 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
118
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Zhejiang Cancer Hospital

Collaborators